Financial Performance - In the fiscal year 2024, the sales revenue increased by 234% to RMB 255.9 million, attributed to the inclusion of Huadongning® in the National Medical Insurance Drug List[8]. - The total revenue for the fiscal year 2024 was approximately RMB 255.9 million, reflecting sales of about 2,105,000 boxes of Huadongning®, with sales revenue and volume increasing by approximately 234% and 740% respectively compared to the previous year[10]. - Other income for the fiscal year 2024 totaled approximately RMB 116.8 million, a decrease of about RMB 13.8 million or 11% from the previous year, primarily due to milestone income from Bayer[10]. - The pre-tax loss for the fiscal year 2024 increased by approximately RMB 38.9 million or 18% to about RMB 250.1 million, mainly due to increased sales and R&D expenses[10]. - Gross profit for the fiscal year ending December 31, 2024, was approximately RMB 124.7 million, with a gross margin of 48.7%, slightly down from 48.8% in the previous year, primarily due to a decrease in sales price from RMB 341.95 to RMB 124.88 per box after inclusion in the national medical insurance catalog[35]. - The company recorded a net cash outflow from operating activities of RMB 418.0 million for the fiscal year ending December 31, 2024, with cash and cash equivalents amounting to RMB 1,139.8 million as of the same date[46]. - For the year ended December 31, 2024, the net cash used in operating activities was RMB 418.0 million, a significant decrease from RMB 889.4 million for the year ended December 31, 2023, primarily due to a pre-tax loss of RMB 250.1 million[48]. - The net cash generated from investing activities for the year ended December 31, 2024, was RMB 10.0 million, compared to RMB 8.1 million for the year ended December 31, 2023, mainly from interest on short-term bank deposits[50]. - The net cash generated from financing activities for the year ended December 31, 2024, was RMB 83.7 million, an increase from RMB 69.1 million for the year ended December 31, 2023, primarily from short-term and long-term bank loans[51]. - The company’s total reserves available for distribution as of December 31, 2024, amounted to RMB 1,747.54 million[110]. Research and Development - R&D expenses for the fiscal year 2024 amounted to approximately RMB 215.1 million, an increase of about RMB 43.6 million or 25% compared to the previous year[10]. - The company is advancing the development of the second-generation glucose kinase activator (GKA) HM-002-1005 for Type 2 diabetes and obesity, with successful results from the single-dose escalation study in the U.S.[13]. - The company is conducting clinical research on dorzagliatin for prediabetes and early-stage Type 2 diabetes, testing new dosages to explore its potential for these indications[14]. - The company is focused on the development of dorzagliatin, with a strong emphasis on R&D led by experienced professionals in the biopharmaceutical industry[68]. - Dorzagliatin is a novel glucose kinase activator (GKA) aimed at restoring blood glucose homeostasis in type 2 diabetes patients[97]. - The company has been granted global rights by Roche to develop dorzagliatin[97]. Market Expansion and Commercialization - The company plans to expand its glucose kinase-targeted therapies into international markets, particularly the U.S., with significant progress in the development of the second-generation glucose kinase activator (HM-002-1005)[8]. - The company is preparing to submit registration applications for dorzagliatin in Macau and Hong Kong markets in 2025[10]. - Following the termination of the exclusive promotion service agreement with Bayer, the company sold approximately 592,000 boxes of Huadongning® in the first two months of 2025, generating net sales of approximately RMB 73.2 million, reflecting a 199% increase compared to the same period in 2024[31]. - The company aims to strengthen its commercialization capabilities through a hub-and-spoke development model, focusing on building internal sales and medical marketing organizations[16]. - The company is investing to expand production capacity to meet anticipated market demand in 2026 and 2027[10]. - The company is actively pursuing new technologies and product development in the biopharmaceutical sector, particularly in innovative drug development[72]. Corporate Governance and Management - The board of directors consists of three executive directors, two non-executive directors, and three independent non-executive directors[194]. - The company has established an independent board evaluation mechanism this year to ensure strong independence and effective judgment[200]. - The evaluation aims to enhance board efficiency and identify areas for improvement and development[200]. - The company has a strong management team with extensive experience in finance, quality assurance, and drug development[91][92][94]. - The company has adopted a competitive compensation policy for employees, including stock options and bonuses, based on industry standards and employee performance[183]. Risks and Financial Position - The company faces various market risks, including currency risk, interest rate risk, credit risk, and liquidity risk, and currently does not have any hedging policies in place[54][58]. - The leverage ratio was reported as meaningless for the year ended December 31, 2024, compared to 165.8% for the year ended December 31, 2023, reflecting changes in financing strategy[60][61]. - The current ratio decreased to 4.0 as of December 31, 2024, from 6.2 as of December 31, 2023, while the quick ratio decreased to 3.7 from 6.1 during the same period, primarily due to increased short-term and long-term loans[60][61]. - The company has bank deposits of RMB 8.9 million pledged to banks, with RMB 1,565,000 at a fixed interest rate of 2.75% pledged for factory construction completion guarantees[63]. - The company has no significant contingent liabilities as of December 31, 2024[66]. Employee and Compensation - The company employed a total of 168 employees as of December 31, 2024, down from 177 employees as of December 31, 2023[183]. - Employee costs for the year ending December 31, 2024, were approximately RMB 154.2 million, compared to RMB 163.3 million for the year ending December 31, 2023, reflecting a decrease of about 5.5%[183]. - The company regularly reviews compensation and benefits to retain key management personnel and attract qualified staff[175]. - The company is committed to providing ongoing training and development programs for employees to enhance their skills and knowledge[183]. Shareholder Information - Major shareholders include ARCH Venture Fund VII, L.P. with 11.85% and Venrock Associates V, L.P. with 9.80%[130]. - The company has no equity-linked agreements other than the pre-IPO and post-IPO share option plans[125]. - The company has not granted any shares or options under the pre-IPO share incentive plan or post-IPO option plan during the reporting period, resulting in 0 shares issued[139]. - The total unexercised stock options as of December 31, 2024, amount to 61,784,143 shares, with an average closing price of HKD 1.51[151].

Financial Data and Key Metrics Changes - The company is transitioning from an innovation drug discovery company to a commercialization-driven company, with significant growth in sales and profitability expected [4][20] - The net sales increased close to 200% compared to the same period in 2024, despite a price reduction due to the NRDL [7][23] - The gross profit margin is targeted to reach 80% over the next few years as the company optimizes its manufacturing processes [50] Business Line Data and Key Metrics Changes - The sales of dorzaglietin have shown a significant increase, with 2,700 hospitals prescribing the drug by the end of 2024, accounting for 81% of total sales in China [9][21] - The company plans to expand its sales force to cover the top 500 hospitals, aiming for RMB 1 billion in sales by 2027 [40][42] Market Data and Key Metrics Changes - The oral anti-diabetic market in China is valued at approximately RMB 30 billion, with dorzaglietin expected to remain a major market force for the next ten years [41] - The company is exploring opportunities in Southeast Asia, where diabetes prevalence is projected to increase significantly [12][13] Company Strategy and Development Direction - The company aims to enhance its commercialization capabilities and establish a strong presence in the market by focusing on key hospitals and leveraging its existing R&D team [40][41] - Future strategies include developing a second-generation glucokinase activator and exploring partnerships for broader market access [14][62] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the drug's effectiveness and safety, highlighting its acceptance in the medical community and among patients [9][21] - The company anticipates a decline in net loss and an increase in profitability as it gains control over its sales and marketing efforts [20][24] Other Important Information - The company has established a strong patent portfolio with 200 approved patents worldwide, enhancing its attractiveness as an investment target [18][19] - The transition from Bayer to in-house sales and marketing is expected to improve control over sales and profitability [20][25] Q&A Session Summary Question: How does the company view the competition from GLP-1 drugs? - Management believes dorzaglietin complements GLP-1 therapies by improving insulin secretion and glucose sensitivity, addressing the underlying causes of diabetes [34][35] Question: What is the market potential for dorzaglietin amid competition? - The company sees immense opportunities in the oral anti-diabetic market in China, with plans to establish a strong internal infrastructure for sales and marketing [40][41] Question: What are the plans for the second-generation drug? - The company aims to find partners for the second-generation glucokinase activator, focusing on both monotherapy and combination therapy strategies [62][63]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第17.06A條而 作出。 華領醫藥（「本公司」）董事（「董事」）會（「董事會」）宣佈，於2025年3月28日，本 公司根據於2018年8月26日有條件批准及採納，並於2018年9月14日起生效的本 公司購股權計劃（「購股權計劃」），向本公司三名執行董事、117名僱員及一名服 務提供商（定義見上市規則）（統稱「承授人」）授出購股權（「購股權」），惟須待承 授人接納後方可作實。購股權賦予承授人權利可認購本公司股本中合共9,700,000 股每股面值0.001美元的新股份（「股份」）。 所授出購股權的詳情如下： 授出日期： 2025年3月28日 所授出購股權的行使價： 每股股份2.48港元，即以下各項中的較高者： iii. 面值每股股份0.001美元。 HUA MEDICINE 華領醫藥 （於開曼群島註冊成立的有限公司） （股份代號：2552） 授 ...

Core Insights - The core product Huadongning® (Dapagliflozin) experienced a significant sales increase of 740% year-on-year, generating sales revenue of 255.9 million RMB, a 234% increase compared to the previous year, marking a milestone for the company in the commercialization process [1][2] Sales and Market Penetration - The inclusion of Huadongning® in the national medical insurance directory has led to a transformation from market access to terminal volume, with sales reaching 2.105 million boxes and coverage expanding to approximately 2,700 hospitals [2][3] - The company has begun building a specialized sales team, with plans to have 100 employees by April 1, 2024, enhancing its market reach and channel management capabilities [3] Financial Performance and Profitability - The company is expected to recognize approximately 1.2435 billion RMB in unamortized contract liabilities as revenue in 2025, indicating a high likelihood of profitability in that year [4] - The CEO anticipates a continuous increase in gross margin from 2025 to 2028, projecting a gross margin of 70% to 80% due to the innovative nature of the product and cost-reduction strategies [4] R&D Pipeline and Competitive Advantage - The company is transitioning from a single product focus to a platform technology approach, enhancing the lifecycle value of its products through a diversified R&D pipeline [5][6] - Significant breakthroughs in the second-generation GKA clinical trials have been achieved, with plans to explore new clinical indications and potential collaborations for combination therapies [5][6] International Expansion and Future Outlook - The company is accelerating its internationalization efforts, with plans to develop the second-generation GKA in obesity-prone regions and submit applications for market entry in Hong Kong and Macau by 2025 [6] - The successful commercialization of Huadongning® post-medical insurance inclusion is seen as a new starting point for the company, with multiple factors expected to catalyze long-term value release [6]

Core Viewpoint - 华领医药-B reported a significant increase in annual revenue and gross profit for the fiscal year ending December 31, 2024, primarily driven by the sales of its core product, 华堂宁, which has been included in the national medical insurance drug list for type 2 diabetes [1][2] Group 1: Financial Performance - The company achieved a revenue of 256 million RMB, representing a year-on-year increase of 234.02% [1][2] - Gross profit reached 125 million RMB, with a year-on-year increase of 233.72% [1] - Research and development expenses amounted to 215 million RMB, reflecting a year-on-year increase of 25.39% [1] Group 2: Product Sales and Market Presence - Approximately 2.105 million boxes of 华堂宁 were sold, generating sales revenue of about 256 million RMB for the fiscal year [1] - In the previous fiscal year, around 251,000 boxes were sold, resulting in sales of approximately 76.6 million RMB [1] - 华堂宁 is now available in about 2,700 hospitals across mainland China [2] Group 3: Financial Stability - As of December 31, 2024, the company maintained a robust balance sheet with cash reserves of 1.14 billion RMB to support its commercialization, business development, and research activities [2]

Core Viewpoint - The company reported a significant increase in revenue and gross profit for the fiscal year ending December 31, 2024, primarily driven by the sales of its core product, Huatangning, which has been included in the national medical insurance drug list in China, indicating strong future sales potential [1][2] Financial Performance - Revenue for the fiscal year reached 256 million RMB, a year-on-year increase of 234.02% [1] - Gross profit amounted to 125 million RMB, reflecting a year-on-year increase of 233.72% [1] - Research and development expenses were 215 million RMB, up 25.39% year-on-year [1] Product Sales and Market Expansion - Approximately 2.105 million boxes of Huatangning were sold, generating sales of about 256 million RMB, compared to 251,000 boxes and 76.6 million RMB in the previous year [1] - Huatangning is now available in around 2,700 hospitals across mainland China [2] - The company has taken over the commercialization of Huatangning from Bayer Pharmaceuticals, with a new sales leader appointed to drive market efforts [2] Future Outlook - The inclusion of Huatangning in the national medical insurance list is expected to significantly boost sales in the coming years [1] - In the first two months of 2025, approximately 592,000 boxes of Huatangning were sold, generating net sales of about 73.2 million RMB, compared to 202,000 boxes and 24.5 million RMB in the same period of 2024, indicating a 199% increase in sales despite stable pricing [2]

Financial Performance - For the fiscal year ending December 31, 2024, the sales revenue increased by 234% to RMB 255.9 million, with approximately 2,105,000 boxes of Huadongning® sold[4] - The company reported a pre-tax loss of approximately RMB 250.1 million, an increase of about 18% compared to the previous year, primarily due to increased sales and R&D expenses[6] - The company generated other income of approximately RMB 116.8 million, a decrease of about 11% from the previous year, mainly from Bayer milestone income amortization[6] - Gross profit for the fiscal year ending December 31, 2024, was approximately RMB 124.7 million, with a gross margin of 48.7%, slightly down from 48.8% in the previous year, primarily due to a decrease in sales price after inclusion in the national medical insurance catalog[19] - The company reported a basic and diluted loss per share of RMB 0.25 for 2024, compared to RMB 0.22 for 2023[52] - The company reported a significant increase in cash outflows from operating activities, with a total decrease of RMB 1,291.4 million in cash and cash equivalents from the previous year[32] Research and Development - The R&D expenses for the fiscal year were approximately RMB 215.1 million, reflecting a 25% increase compared to the previous year[6] - The company is advancing the development of dorzagliatin in prediabetes and early-stage type 2 diabetes through the SENSITIZE 3 clinical study, testing new dosages of 25 mg and 50 mg[10] - The company has allocated RMB 291.4 million (39%) for the research and development of Dorzagliatin, with no funds utilized as of December 31, 2024[92] - A total of RMB 201.8 million (27%) has been designated for the launch and commercialization of Dorzagliatin, with no funds utilized as of December 31, 2024[92] - The company has set aside RMB 82.2 million (11%) for new product and diabetes treatment technology development, with RMB 36.4 million utilized as of December 31, 2024[92] Market Expansion and Product Development - The company has made significant progress in preparing to expand its glucose kinase-targeted therapies into international markets, particularly the U.S.[5] - The company plans to submit registration applications for dorzagliatin in Macau and Hong Kong in 2025[5] - In 2024, the company made significant progress in expanding its glucose kinase-targeted therapies for blood sugar balance into international markets, particularly the U.S., completing the SAD study results for the second-generation GKA (HM-002-1005) for T2D and obesity patients[8] - The company aims to explore new indications for dorzagliatin, including metabolic disorders and neurodegenerative diseases, while continuing to invest in digital technology platforms and AI to enhance brand opportunities[14] Financial Position and Cash Flow - As of December 31, 2024, the cash balance was approximately RMB 1,139.8 million, supporting commercial operations and R&D activities[6] - The company recorded a net cash outflow from operating activities of RMB 418.0 million for the year ending December 31, 2024, with cash and cash equivalents at RMB 1,139.8 million[30] - As of December 31, 2024, the net current assets decreased to RMB 1,006.2 million from RMB 1,320.4 million as of December 31, 2023, primarily due to net cash outflows during the year[37] - The liquidity ratios showed a decline, with the current ratio dropping from 6.2 in 2023 to 4.0 in 2024, and the quick ratio decreasing from 6.1 to 3.7[46] Operational Expenses - Selling expenses rose from RMB 79.8 million to RMB 153.2 million, driven by increased promotional spending and labor costs[25] - Administrative expenses decreased from RMB 124.1 million to RMB 116.8 million, attributed to lower labor costs and reduced marketing and consulting fees[23] - Research and development expenses increased from RMB 171.5 million in the previous year to RMB 215.1 million, with clinical trial costs for dorzagliatin rising significantly[27][29] Customer and Revenue Insights - Major customers contributed significantly to revenue, with Customer A generating RMB 91,383,000 in 2024, up from RMB 35,036,000 in 2023[63] - The company anticipates a substantial increase in sales of Huatangning® in the coming years following its inclusion in the national medical insurance catalog[18] Compliance and Governance - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions during the year[95] - The annual financial performance for the year ended December 31, 2024, has been reviewed by the audit committee and Deloitte[98] - The annual report for the year ended December 31, 2024, will be published on the stock exchange and the company's website[101] - The company has confirmed compliance with the standard code for securities transactions by directors throughout the year[94] Future Plans - The company is investing to expand production capacity to meet anticipated market demand in 2026 and 2027[5] - The company plans to recognize unamortized contract liabilities of RMB 1,243,499,000 as income in 2025 following the termination of an exclusive promotion service agreement[88]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 行政總裁兼執行董事 陳力博士 香港，2025年3月17日 於本公告日期，董事會成員包括執行董事陳力博士、林潔誠先生及張怡博士； 非執行董事Robert Taylor Nelsen先生及Fangxin Li博士；以及獨立非執行董事 William Robert Keller先生、徐耀華先生及張耀樑先生。 （於開曼群島註冊成立的有限公司） （股份代號：2552） HUA MEDICINE 董事會召開日期 華領醫藥 華領醫藥（「本公司」及其附屬公司「本集團」）董事會（「董事會」）茲通告，本公司 謹定於2025年3月27日（星期四）舉行董事會會議，以考慮及通過，其中包括，本 集團截至2024年12月31日止的年度全年業績，及建議之末期股息（如有），以及處 理其他事項。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告乃由華領醫藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交 易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例第571章證券及 期貨條例第XIVA部而作出。 HUA MEDICINE 華領醫藥 （於開曼群島註冊成立的有限公司） 茲提述本公司日期為2024年11月22日之公告（「11月公告」）。本公告所用界定詞彙 與11月公告所界定者具有相同涵義。誠如11月公告所載，於2024年11月21日，華 領上海向拜耳發出書面通知，表示有意自2025年1月1日起，將本公司開發用於治 療2型糖尿病的首創葡萄糖激酶激活劑华堂宁® （dorzagliatin片劑）在中國的商業化 責任過渡至本公司，且為實現過渡，本公司有權並計劃自2025年1月1日起終止協 議。 董事會謹此知會本公司股東，於2024年12月31日，華領上海根據協議向拜耳送達 正式終止通知，自2025年1月1日起生效。拜 ...

（於開曼群島註冊成立的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HUA MEDICINE 華領醫藥 承董事會命 行政總裁兼執行董事 陳力博士 （股份代號：2552） 關於华堂宁®的業務最新發展 內幕消息 本公告乃由華領醫藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交 易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例第571章證券及 期貨條例第XIVA部而作出。 於2020年8月17日，有關各方就华堂宁®在中國的商業化建立合作關係並訂立相 關的獨家推廣服務協議（「協議」）。根據協議，拜耳獲得华堂宁®於中國的獨家商 業化權。自拜耳合作以來，已達成數個與华堂宁®相關的里程碑。該等里程碑包 括：华堂宁®於2022年10月獲中國國家醫藥品監督管理局批准在中國銷售；其自 2024年1月1日起納入國家醫保藥品目錄(NRDL)；截至本公告日期，其已進入中 國2,000多家醫院；及其最近被中華醫學會糖尿病學分會納入 ...